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Abstract There is a growing evidence base on the cost
effectiveness of malaria interventions. However, certain
characteristics of malaria decision problems present a
challenge to the application of healthcare economic eval-
uation methods. This paper identifies five such challenges.
The complexities of (i) declining incidence and cost
effectiveness in the context of an elimination campaign; (ii)
international aid and its effect on resource constraints; and
(iii) supranational priority setting, all affect how health
economists might use a cost-effectiveness threshold. Con-
sensus and guidance on how to determine and interpret
cost-effectiveness thresholds in the context of internation-
ally financed elimination campaigns is greatly needed. (iv)
Malaria interventions are often complimentary and evalu-
ations may need to construct intervention bundles to rep-
resent relevant policy positions as sets of mutually
exclusive alternatives. (v) Geographic targeting is a key
aspect of malaria policy making that is only beginning to
be addressed in economic evaluations. An approach to
budget-based geographic resource allocation is described
in an accompanying paper in this issue and addresses some
of these methodological challenges.
Key Points for Decision Makers
The use of cost-effectiveness thresholds is
complicated by the disease elimination objective and
international aid.
To be relevant to key policy questions, economic
evaluations may need to evaluate compatible (rather
than mutually exclusive) interventions and provide
information to support geographic targeting.
1 Introduction
Total annual spending on malaria has grown to over US$
2.6 billion globally [1]. The current availability of resour-
ces represents an arguably unprecedented opportunity to
reduce the global public health burden of malaria and
perhaps eradicate the disease altogether. Promising gains
have been made, with global malaria-associated mortality
decreasing by 60% between 2000 and 2015 (down to an
estimated 438,000 deaths) [1]. It is important to continue to
make the most of the currently available resources by
spending in a way that maximises impact.
Healthcare economic evaluation can offer useful infor-
mation to support this goal by appraising the balance of
costs and consequences of technologies or services in dif-
ferent contexts. A recent review by Gray and Wilkinson
describes the development of economic evaluation
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methods [2] including two key initiatives for priority set-
ting in low and middle income countries (LMICs) (i) the
World Health Organisation’s (WHO) Generalised Cost
Effectiveness Analysis (GCEA) [3] and (ii) the more recent
reference case, an initiative to support methodological
standardisation backed by the Bill and Melinda Gates
Foundation [4].
In most endemic countries in Asia and Latin America,
and increasingly in Africa, malaria decision making takes
place within the context of a disease elimination goal,
though the best path to achieving this goal is far from clear.
Key questions facing malaria decision makers are whether,
where and when to deploy several interventions and pro-
grammes, including:
• Scale up vector control (typically through long-lasting
insecticide treated bed nets).
• Scale up access to malaria diagnosis and treatment.
• Forms of mass drug administration (including mass
screening and treatment).
• Active case follow-up.
• Deployment of an emergent malaria vaccine.
The malaria economic evaluation evidence base to guide
policy makers is substantial and growing. In 2011 a sys-
tematic review of the cost and cost effectiveness of malaria
control interventions identified 43 economic evaluations
published between 2000 and 2010 [5]. A broader review of
economic evaluation in LMICs published in 2015 found
that malaria comprised 20% (n = 41) of the published
literature between 2000 and 2013 [6]. The most recent and
broadest review identifies a further 29 malaria economic
evaluations published between 2012 and May 2014, rep-
resenting a 13% share of the literature across all disease
and income settings [7]. Since different time periods are
covered by the 2011 and 2016 reviews, there are at least 72
malaria economic evaluations published to date, 40% of
which have been published since 2012. However, there are
some important idiosyncrasies; this paper identifies some
common characteristics of malaria decision problems that
affect both the application of economic evaluation methods
and interpretation of results.
2 Elimination: Intervention Cost-Effectiveness
Decreases with Incidence (Or Appears To)
In the context of disease elimination it is possible to draw a
distinction between two types of economic evaluation;
(i) evaluation of the policy of elimination (or eradication
[8]); and (ii) evaluation of the component interventions
required to achieve elimination.
Economic evaluation of malaria or other elimination
campaigns are relatively uncommon; a systematic review
in 2015 identified 43 economic analyses, though many are
not economic evaluations1 [10]. Such evaluations are
methodologically challenging due to the complexity of
elimination campaigns and expected impacts. In malaria
the expected benefits of elimination are not only to popu-
lation health but various other sectors including (though
evidence is mixed) education [11, 12], tourism [13], and
economic productivity [14, 15]. Cost benefit or cost con-
sequence analysis [16] can be used to appraise the multi-
sectoral impacts of elimination, though concrete results
may remain elusive. To capture the full costs and benefits
of an elimination campaign, the evaluation time horizon
must extend some years beyond the expected date of
elimination. Such analysis inherently entails a great degree
of uncertainty, in particular due to influence of secular
trends that can play a decisive role in driving transmission.
It is very difficult to anticipate the impact of economic
development, deforestation or climate change on malaria,
and such factors could play important roles over the course
of 10 or 20 years. There is also a risk of failure, either
through never reaching elimination [17] or from a post-
elimination resurgence of transmission [18].
Routine economic evaluations of malaria interventions
typically take shorter time horizons, evaluating the
1 Defined by Drummond et al. as ‘‘the comparative analysis of
alternative courses of action in terms of their costs and consequences’’
[9].
Fig. 1 General relationship between intervention cost effectiveness
and declining disease. (i) Intervention with fixed costs with respect to
incidence, including prevention activities such as vector control or
vaccination; (ii) Intervention costs are partially variable with
incidence, including diagnosis and treatment based interventions.
Notation: a ¼ incidence; c ¼ cost; e ¼ effectiveness; t ¼ time. A
time horizon that excludes post-elimination benefits is assumed
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differences in direct health impact or reductions in trans-
mission over the short term or up to the point of elimination
[19]. Evaluations comparing specific interventions rarely,
if ever, include post-elimination benefits. This is important
because cost effectiveness can appear to decline as malaria
transmission falls on the path to elimination. Malaria
intervention costs are wholly or partially fixed with respect
to malaria incidence. The costs of prevention activities
such as bed net distribution are unaffected by malaria
incidence, as is the cost of mass drug administration or
improved diagnosis. Even for case management focused
interventions, the commodity costs that would be variable
with incidence comprise a minor proportion of total pro-
gramme costs [20]. In other words, a non-negligible portion
of intervention costs is fixed with respect to malaria inci-
dence. Any decrease in cost due to lower incidence will be
proportionally less than the change in health impact and the
cost-effectiveness ratio will rise. This is illustrated in Fig. 1
with two arbitrary interventions, one with fixed costs with
respect to incidence and one with partially fixed costs.
If the campaign is successful and incidence declines, so
too (almost paradoxically) does the apparent cost effec-
tiveness of the interventions. At some point on the decline
in transmission the relevant incremental cost-effectiveness
ratios (ICERs) will no longer fall under the appropriate
cost-effectiveness threshold (CET) (see Box 1 and Box 2).
Prima facie, it is not possible to achieve malaria elimina-
tion without investing in cost ineffective interventions
because the benefits of investing in the late phases of
malaria elimination lie in the difficult-to-define post-elim-
ination period.
An opportunity to move past this challenge perhaps lies
in the elimination decision itself. Whether or not it is based
on quantitative analysis of the costs and benefits of elimi-
nation, a political decision to aim for elimination implies
that spending on this goal is perceived to be cost effective
compared with alternative spending in the health sector. If
the elimination goal is a genuine commitment, it perhaps
implies a shift in the objective of routine malaria economic
evaluation from allocative efficiency across the health
sector in general, to what could be considered technical
efficiency within the elimination campaign. That is, for
decisions on the allocation of malaria funds to specific
interventions the CET may be discarded as the represen-
tative of resource constraints in favour of a budget, which
for malaria is often known and ring-fenced [21]. In this
case the appropriate budget size for the malaria elimination
campaign remains an open question; one with diverse
stakeholders and further complications to the application of
a CET that reflects health-sector constraints (Sect. 4).
Box 1 Cost-effectiveness priority setting: a brief summary
Comprehensive descriptions of economic evaluation methods can be found
elsewhere [9, 21, 22]. The most common frameworks, cost-effectiveness or cost
utility analysis, typically include the following steps:
• Define a decision problem in terms of a set of alternative healthcare technologies
or services (interventions)
• Measure or model intervention costs and effects
• Express the differences between competing interventions on the cost
effectiveness frontiera as incremental cost effectiveness ratios (ICERs)b
• Use a cost-effectiveness threshold (CET) to define the intervention with the
highest ICER below the CET as the optimal choice
Cost
Eﬀect
Dominated (absolutely 
or by extension)
Cost eﬀecveness froner
Δ Cost
Δ Eﬀect
ICER
A
B
D
F
C E
a All interventions that are not dominated. Interventions A, B, D and F in the example
b The difference in costs between two alternatives divided by the difference in effects, reflecting the value in replacing one intervention with
another
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An elimination policy does not mean that routine economic
evaluation has reached the end of the road and that all spending
to reach this goal canbe considered value formoney.Economic
evaluation remains a valuable source of information that can
support planning to achieve maximum impact on health, but
consensus and clearer guidance is needed for analysts and users
in the application and interpretationof economic evaluations in
the context of disease elimination.
3 International Aid: Available Resources Exceed
Local Funding Constraints
In the past decade, international aid has transformed
malaria control and elimination efforts. In 2014, recipient
countries reported receiving almost US$2 billion in finan-
cial aid for malaria control and elimination, comprising
76% of all malaria spending (Fig. 2) [1]. Putting to one
side the complications of using CETs in the context of
disease elimination, how does international aid affect
economic evaluation decision rules?
The purpose of international aid is to overcome the
severe resource constraints faced by LMICs. While there is
a longstanding debate surrounding so-called vertical aid
[27, 28], earmarked disease-specific funding continues to
facilitate the implementation of malaria programmes that
otherwise would not have been affordable. As outlined in
Box 2, a CET is used to represent the resource constraints
of the society or healthcare provider. Regardless of the
CET chosen, on introducing a non-negligible sum of aid
the CET would, in theory, need to be raised to reflect the
increase in healthcare services now affordable to this
society. It may be that across the health sector total aid
inflows are not significant; however, in many countries
there is substantial additional financing directed specifi-
cally towards malaria control and elimination. In these
contexts a CET that accurately reflects governmental or
societal constraints may be inaccurate in reflecting resource
constraints in malaria planning.
Probabilistic analysis and cost-effectiveness acceptabil-
ity curves enable analysts to consider a range of possible
CETs. Nevertheless, again, consensus is needed on whether
and how to adjust an expected health-sector CET where aid
affects affordability of malaria control and elimination
programmes.
4 International Aid: Supranational Priority
Setting
Economic evaluation typically aims to address allocative
efficiency within a nation state. However, before interna-
tional aid arrives in-country to be allocated to malaria
interventions, a series of decisions have already been made
regarding which disease areas and which countries to pri-
oritise. No formal economic analysis of supranational pri-
ority setting of malaria funds has been published to our
knowledge.
There are several important factors that affect the
interpretation of cost-effectiveness evidence for suprana-
tional priority setting. As outlined in Box 2, standard
decision rules (including GDP indexed CETs) are intended
to reflect the resource constraints of a particular country.
Therefore, conclusions about whether an intervention is
cost effective (or not) to a large degree reflect the afford-
ability of the intervention in that context as much as the
efficiency with which investment may be converted to
health gains. For example, a multi-country study of pan-
demic preparedness found that, in general, stockpiling
antivirals is not cost-effective for LMICs but may be cost
effective in high-income countries [29]. As the authors
note, the use of GDP based CETs means this conclusion
reflects local affordability and does not reflect where
investment would yield the most health gains. The reverse
would likely be true [30]. Decision makers and analysts
should therefore not use GDP-based CETs for between-
country priority setting. Notably, recent work on decision
rules for health system strengthening in the context of
supranational priority setting focuses on budget allocation
rather than threshold analysis [31]. To an extent, GDP-
based CETs may remain relevant to supranational priority
setting in terms of allocative efficiency within the health
sector that aid is delivered into. However regional malaria
elimination or global eradication is a weakest link global
public good, requiring effort from all affected countries for
success [17]. GDP-based CETs are a decision framework
for optimal allocation of healthcare resources at the
national level yet regional malaria elimination policy must
consider more than simply the efficient allocation of
resources from a country perspective.
Supranational priority setting perhaps implies a role for
a common or global CET [32], matching the perspective of
the funder. That is, health gains are valued equally in all
countries and funds directed to where impact is greatest. A
Box 2 Cost-effectiveness thresholds
The cost-effectiveness threshold (CET) is considered to represent the
willingness-and-ability-to-pay of the Ministry of Health or society
in general, and would ideally be set at such a level that it reasonably
reflects real budget constraints. In theory, the CET is equal to the
opportunity cost of alternative public healthcare spending. Defining
an accurate CET is a challenge and it is often indexed to the national
gross domestic product (GDP) per capita. In low and middle income
countries (LMICs), thresholds of 19 and 39 GDP per capita are
commonly used [23], though a recent study suggests a lower
threshold may be more appropriate [24]. An earlier review by
Shillcutt et al. summarises the methodological debate in defining
CETs in LMICs [25]
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global CET might reflect supply-side2 constraints of
international aid budgets or demand-side norms regarding
the extent to which poorer countries should be supported to
provide healthcare services that would otherwise be unaf-
fordable. GiveWell, an advisory organisation for charity
donors, is effectively applying a global CET of US$5000
per life saved in their assessments of philanthropic causes
and organisations [33].
Ultimately, if malaria elimination is cost effective (and
political commitments to achieve elimination suggests it is
considered to be in the countries that have made them) then
other factors such as the rate at which local health systems can
efficiently absorb additional financing, the period for which
this can be sustained, equity considerations and rises in
domestic financing may drive international aid allocations.
5 Choosing Between Compatible Interventions
In economic evaluation methodology, a decision problem
is typically structured as a set of mutually exclusive
alternatives (see Box 1). Some malaria decision problems
such as the choice of first-line therapy or diagnostic test fit
this framework well [34–36]. In other cases, the decision
problem entails choosing between interventions that are not
mutually exclusive but compatible or even complimentary,
such as bed nets and community health workers. In this
case, it is not necessary to choose one or the other, it is
entirely possible to deliver both. This complicates the
rationale for constructing a cost-effectiveness frontier and
calculating incremental cost-effectiveness ratios (since
these reflect the value of replacing one intervention with
another). There are two options available when addressing
complimentary interventions.
1. Use a base-case comparator scenario for all
interventions.
2. Construct intervention bundles defined as mutually
exclusive alternatives.
In the first approach, the costs, effects and cost-effective-
ness ratios of intervention options are all expressed in com-
parison to a common baseline, most likely a null or ‘‘no
additional intervention’’ scenario, which is similar in this
respect to the generalised cost effectiveness analysis (GCEA)
framework [3]. These generalised cost-effectiveness ratios
allow the reader to make a judgement about which inter-
ventions, in isolation, yield the greatest health gains per unit
of investment. The cost-effectiveness rank could be applied to
determining the order in which interventions are added to a
package of services but may be less applicable when choosing
one intervention instead of another (when an incremental
cost-effectiveness ratio based on the difference in costs and
effects between the two interventions is required). An addi-
tional limitation is that intervention interactions are not
accounted for. This approach assumes that the costs and, in
particular, effects of intervention A are unchanged by the
presence of intervention B, which is rarely a tenable
assumption for interventions addressing the same disease.
To incorporate both intervention compatibility and inter-
actions, several malaria economic evaluations have con-
structed priority setting landscapes based on discrete packages
of interventions [37–39]. Intervention bundles can then be
treated as mutually exclusive alternatives and incremental
analysis applied to assess the value of switching from one
package to another. A limitation of this approach is that the
intervention combinations are defined a priori and may
restrict the decision space since it may not be possible to
include all possible combinations. Input from decision makers
into the design of intervention packages will improve the
relevance of the evaluation to policy decisions. Evidence
users should take care not to interpret the package with the
lowest cost-effectiveness ratio as the optimal choice. This
applies to all economic evaluation results but can be partic-
ularly tempting with evaluations of intervention bundles.
6 Geographic Targeting
The epidemiology of malaria varies considerably between
different geographical areas. A core aspect of priority
setting in malaria control and elimination is to determine
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2 Ochalek et al. introduce the concept of supply- and demand-side
perspectives on the cost-effectiveness threshold broadly reflecting
resource contraints and societal norms, respectively [24].
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which interventions, or combinations of interventions, are
provided where.
There are several options to address geographic
heterogeneity in economic evaluation. Stratification of
results, sensitivity analysis or scenario analysis can be used
to present the cost effectiveness of healthcare interventions
in contexts with certain characteristics. Readers are then
free to match their context of interest to the closest
example given. In this approach the reader still has a
degree of work to do in translating from illustrative
examples to applied policy, particularly if targeting
resources across a large number of geographical units such
as districts or townships. Moreover, any distinction
between heterogeneity and uncertainty in results may be
lost. Calculation of costs, effects and cost effectiveness in
all geographic units of interest would provide a decision
maker with a fuller picture of the decision landscape.
Decision rules or constraints can then be applied to yield a
recommended geographic allocation of interventions
according to a CET, or, given the limitations discussed
here, direct allocation of a relevant budget. Two recent
studies address the geographic allocation of resources in
malaria planning [26, 37] but such examples are rare and
methods are varied.
7 Summary
We identify five areas where the realities of malaria deci-
sion problems affect the application of economic evalua-
tion methods. The complexities of (i) declining incidence
and cost effectiveness in the context of elimination; (ii)
international aid and resource constraints; and (iii) supra-
national priority setting, all affect the way in which health
economists might use a CET. Guidance and consensus
regarding best practice on when and how to use a CET for
malaria economic evaluation, and the selection or calcu-
lation of this threshold, is greatly needed. Alternatively, a
policy of malaria elimination may allow economic evalu-
ation to focus on direct budget allocation within the
elimination campaign. (iv) In order to properly inform
priority setting in malaria policy, economic evaluations
must be able to assess combinations of compatible inter-
ventions, rather than sets of mutually exclusive alterna-
tives. Assessment of exhaustive sets of intervention
combinations is not possible and communication with
policy makers will be essential to construct relevant eval-
uation questions. (v) Geographic priority setting is a core
element of planning in both the control and elimination of
malaria. Economic evaluation can do more to support this
priority setting by incorporating geographic heterogeneity
into analyses and making a clear distinction between
heterogeneity and uncertainty.
In an accompanying paper in this issue [40] we outline an
approach to geographic resource allocation inmalaria planning
that addresses several of the challenges outlined in this paper.
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